Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
Background Sequential cohort design (SCD) applying matching for propensity scores (PS) in accrual periods has been proposed to mitigate bias caused by channeling when calendar time is a proxy for strong confounders. We studied the channeling of patients according to atorvastatin and simvastatin initiation in Finland, starting from the market introduction of atorvastatin in 1998, and explored the SCD PS approach to analyzing the comparative effectiveness of atorvastatin versus simvastatin in the prevention of cardiovascular events (CVE). Methods Initiators of atorvastatin or simvastatin use in the 45–75-year age range in 1998–2006 were characterized by their propensity of receiving atorvastatin over simvastatin, as estimated for 17 six-month periods. Atorvastatin (10 mg) and simvastatin (20 mg) initiators were matched 1:1 on the PS, as estimated for the whole cohort and within each period. Cox regression models were fitted conventionally, and also for the PS matched cohort and the periodically PS matched cohort, to estimate the hazard ratios (HR) for CVEs. Findings Atorvastatin (10 mg) was associated with a 11%–12% lower incidence of CVE in comparison with simvastatin (20 mg). The HR estimates were the same for a conventional Cox model (0.88, 95% confidence interval 0.85–0.91), for the analysis in which the PS was used to match across all periods and the Cox model was adjusted for strong confounders (0.89, 0.85–0.92), and for the analysis in which PS matching was applied within sequential periods (0.88, 0.84–0.92). The HR from a traditional PS matched analysis was 0.80 (0.77–0.83). Conclusions The SCD PS approach produced effect estimates similar to those obtained in matching for PS within the whole cohort and adjusting the outcome model for strong confounders, but at the cost of efficiency. A traditional PS matched analysis without further adjustment in the outcome model produced estimates further away from unity.
References
[1]
Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90: 777–790.
[2]
Seeger JD, Williams PL, Walker AM (2005) An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 14: 465–476. doi: 10.1002/pds.1062
[3]
Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, et al. (2013) Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf 22: 810–818 DOI:10.1002/pds.3386.
[4]
Dusetzina SB, Mack CD, Stürmer T (2013) Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics. PLoS One 8: e63973 DOI:10.1371/journal.pone.0063973.
[5]
Wahl PM, Gagne JJ, Wasser TE, Eisenberg DF, Rodgers JK, et al. (2012) Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf 2012 35: 407–416. doi: 10.2165/11594770-000000000-00000
[6]
Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S (2012) Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology 23: 238–246 DOI:10.1097/EDE.0b013e3182459d7d.
[7]
Halava H, Helin-Salmivaara A, Junnila J, Huupponen R (2009) Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. Eur J Clin Pharmacol 65: 927–933. doi: 10.1007/s00228-009-0664-1
[8]
Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, et al. (2009) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106: 86–94 DOI:10.1111/j.1742–7843.2009.00494.x.
[9]
WHO. About the ATC/DDD system. Available http://www.whocc.no/atcddd/. Accessed 15 Aug 2013.
[10]
Weng TC, Yang YH, Lin SJ, Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharmacol Ther 35: 139–151 DOI:10.1111/j.1365–2710.2009.01085.x.
[11]
Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423–1430. doi: 10.1136/bmj.326.7404.1423
[12]
Korhonen MJ, Huupponen R, Ruokoniemi P, Helin-Salmivaara A (2009) Protopathic bias in observational studies on statin effectiveness. Eur J Clin Pharmacol 65: 1167–1168. doi: 10.1007/s00228-009-0701-0
[13]
Parsons LS. Using SAS software to perform a case-control match on propensity score in an observational study. Paper 225–25. Available: http://www2.sas.com/proceedings/sugi25/2？5/po/25p225.pdf. Accessed 15 Aug 2013.
[14]
Austin P (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statist Med 28: 3083–3107 DOI:10.1002/sim.3697.
[15]
Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-R？ih？ P, et al. (2005) The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 12: 132–137. doi: 10.1097/01.hjr.0000140718.09768.ab
[16]
Tolonen H, Salomaa V, Torppa J, Sivenius J, Immonen-R？ih？ P, et al. (2007) FINSTROKE register. The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. Eur J Cardiovasc Prev Rehabil 14: 380–385. doi: 10.1097/01.hjr.0000239466.26132.f2
[17]
European Medicines Agency. Cerivastatin. Available: http://www.ema.europa.eu/ema/index.jsp?c？url=pages/medicines/human/referrals/Ceri？vastatin/human_referral_000108.jsp. Accessed 15 Aug 2013.
[18]
Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salminen A (2010) Impact of restricted reimbursement on the use of statins in Finland - a register-based study. Med Care 48: 761–766. doi: 10.1097/mlr.0b013e3181e41bcb
[19]
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437–2445. doi: 10.1001/jama.294.19.2437
[20]
Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS (2008) Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 30: 195–205. doi: 10.1016/j.clinthera.2008.01.003
[21]
Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, et al. (2008) Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc 83: 1316–1325. doi: 10.4065/83.12.1316
[22]
Wilke RA, Berg RL, Linneman JG, Zhao C, McCarty CA, et al. (2008) Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository. Basic Clin Pharmacol Toxicol 103: 354–359. doi: 10.1111/j.1742-7843.2008.00291.x
[23]
Simpson RJ Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, et al. (2009) Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc 84: 1065–1072. doi: 10.4065/mcp.2009.0298
[24]
Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S (2012) Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf 21: 697–709 DOI:10.1002/pds.2256.
[25]
Dilokthornsakul P, Chaiyakunapruk N, Schumock GT, Lee TA (2012) Estimating time-specific propensity scores: a case study of the effectiveness of inhaled long-acting beta-agonists on asthma exacerbations. Poster number 146. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 23–26, 2012 CCIB Barcelona, Spain.
